Literature DB >> 31740054

Battle tactics against MMP-9; discovery of novel non-hydroxamate MMP-9 inhibitors endowed with PI3K/AKT signaling attenuation and caspase 3/7 activation via Ugi bis-amide synthesis.

Mohammed Salah Ayoup1, Manar Ahmed Fouad2, Hamida Abdel-Hamid2, El Sayed Ramadan2, Marwa M Abu-Serie3, Ahmed Noby4, Mohamed Teleb5.   

Abstract

Matrix metalloproteinases (MMPs) are major modulators of the tumor microenvironment. They participate in extracellular matrix turnover, tumor growth, angiogenesis and metastasis. Accordingly, MMPs inhibition seems to be ideal solution to control cancer. Many MMPs inhibitors have been introduced ranging from hydroxamate-based peptidomimetics to the next generation non-hydroxamate inhibitors. Among MMPs, MMP-9 is attractive druggable anticancer target. Studies showed that inhibiting AKT, the central signaling node of MMP-9 upregulation, provides additional MMP-9 blockade. Furthermore, caspase-dependent AKT cleavage leads to cell death. Herein, Ugi MCR was utilized as a rapid combinatorial approach to generate various decorated bis-amide scaffolds as dual MMP-9/AKT inhibitors endowed with caspase 3/7 activation potential. The target adducts were designed to mimic the thematic structural features of non-hydroxamate MMP inhibitors. p-Nitrophenyl isonitrile 1 was utilized as structure entry to Ugi products with some structural similarities to amide-based caspase 3/7 activators. Besides, various acids, amines and aldehydes were employed as Ugi educts to enrich the SAR data. All adducts were screened for cytotoxicity against normal fibroblasts and three cancer cell lines; MCF-7, NFS-60 and HepG-2 utilizing MTT assay. 8, 11 and 28 were more active and safer than doxorubicin with single-digit nM IC50 and promising selectivity. Mechanistically, they exhibited dual MMP-9/AKT inhibition at single-digit nM IC50 with excellent selectivity over MMP-1,-2 and -13, and induced >51% caspase 3/7 activation. Consequently, they induced >49% apoptosis as detected by flow cytometric analysis, and inhibited cell migration (metastasis) up to 97% in cancer cells. Docking simulations were nearly consistent with enzymatic evaluation, also declared possible binding modes and essential structure features of active compounds. In silico physicochemical properties, ligand efficiency and drug-likeness metrics were reasonable for all adducts. Interestingly, 8 and 28 can be considered as drug-like candidates.
Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  AKT; Anticancer; Bis-amide; Caspase 3/7; MMP-9; Ugi

Mesh:

Substances:

Year:  2019        PMID: 31740054     DOI: 10.1016/j.ejmech.2019.111875

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  5 in total

1.  Enhancing the Anticancer Potential of Targeting Tumor-Associated Metalloenzymes via VEGFR Inhibition by New Triazolo[4,3-a]pyrimidinone Acyclo C-Nucleosides Multitarget Agents.

Authors:  Mohamed Nabil Abd Al Moaty; El Sayed Helmy El Ashry; Laila Fathy Awad; Nihal Ahmed Ibrahim; Marwa Muhammad Abu-Serie; Assem Barakat; Mezna Saleh Altowyan; Mohamed Teleb
Journal:  Molecules       Date:  2022-04-08       Impact factor: 4.927

2.  Triacrylamide-Based Adhesives Stabilize Bonds in Physiologic Conditions.

Authors:  F S de Lucena; S H Lewis; A P P Fugolin; A Y Furuse; J L Ferracane; C S Pfeifer
Journal:  J Dent Res       Date:  2022-01-09       Impact factor: 8.924

Review 3.  Digestive Inflammation: Role of Proteolytic Dysregulation.

Authors:  Vincent Mariaule; Aicha Kriaa; Souha Soussou; Soufien Rhimi; Houda Boudaya; Juan Hernandez; Emmanuelle Maguin; Adam Lesner; Moez Rhimi
Journal:  Int J Mol Sci       Date:  2021-03-10       Impact factor: 5.923

Review 4.  Two decades of recent advances of Ugi reactions: synthetic and pharmaceutical applications.

Authors:  Manar Ahmed Fouad; Hamida Abdel-Hamid; Mohammed Salah Ayoup
Journal:  RSC Adv       Date:  2020-11-23       Impact factor: 4.036

5.  Design and synthesis of new bis(1,2,4-triazolo[3,4-b][1,3,4]thiadiazines) and bis((quinoxalin-2-yl)phenoxy)alkanes as anti-breast cancer agents through dual PARP-1 and EGFR targets inhibition.

Authors:  Fatma M Thabet; Kamal M Dawood; Eman A Ragab; Mohamed S Nafie; Ashraf A Abbas
Journal:  RSC Adv       Date:  2022-08-19       Impact factor: 4.036

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.